Table 1.
Disease history and baseline characteristics of patients with HCL
| Characteristic | N = 12 |
|---|---|
| Median age (range), y | 55.5 (38-78) |
| Sex, n (%) | |
| Male | 12 (100.0) |
| Baseline ECOG performance status score, n (%) | |
| 0 | 7 (58.3) |
| 1 | 5 (41.7) |
| Median time from initial diagnosis to first dose (range), y | 5.1 (3.0-24.0) |
| Median time from end of last regimen to first dose (range), mo | 31.6 (3.0-53.8) |
| Median number of previous therapies (range) | 2 (1-5) |
| Cytopenia at study entry, n (%) | |
| Anemia (≤110 g/L) | 6 (50.0) |
| Neutropenia (≤1.5 × 109/L) | 6 (50.0) |
| Thrombocytopenia (≤100 × 109/L) | 7 (58.3) |
| Missing | 2 (16.7) |
| Median laboratory values (range)∗ | |
| Hemoglobin (g/dL) | 109.5 (91.0-161.0) |
| Platelet count (109/L) | 64.5 (32.0-182.0) |
| Absolute neutrophil count (109/L) | 1.55 (0.8-3.8) |
ECOG, Eastern Cooperative Oncology Group.
∗
Ten patients had cytopenias as the reason for starting a new HCL therapy. Neutropenia was given as the reason for 3 patients, anemia for 3 patients, and thrombocytopenia for 4 patients. The reason for new therapy was missing in 2 patients.